Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
961-980 of 2,120 trials

Tocilizumab for Painful Chronic Pancreatitis

We are studying whether tocilizumab can help reduce pain and improve quality of life for people with chronic pancreatitis. The trial will compare its effects to a placebo treatment.

Chronic Pancreatitis3-6 monthsEfficacy phase (II)Standard MedicinesGastroenterologyInternal Medicine

Stage IV Non-Small Cell Lung Cancer: Immunotherapy and Radiotherapy Study

We are exploring whether combining immunotherapy with extensive radiotherapy is safe and effective for patients with stage IV non-small cell lung cancer. This study will help us understand the treatment's impact on health and quality of life.

Non-small Cell Lung Cancer (Stage IV)>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesOncologyPulmonology

Metastatic Colorectal Cancer: Personalized Treatment Study

We are investigating whether tailored therapies based on genetic testing can improve treatment outcomes for patients with metastatic colorectal cancer. This study aims to assess the effectiveness and safety of these new treatment options.

Metastatic Colorectal CancerEfficacy phase (II)No PlaceboInvestigational MedicinesGastroenterologyOncology

Breast Cancer: Personalized Treatment with Capivasertib

We are studying a new treatment combining capivasertib with letrozole for women with hormone receptor positive breast cancer. This trial aims to see if this approach improves survival compared to standard treatment.

Hormone Receptor Positive HER2 Negative Breast Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesEndocrinologyOncology

Cardiac Arrest: Amiodarone Treatment Study

We are investigating whether giving amiodarone to critically ill patients after a cardiac arrest can lower the risk of death and serious heart rhythm problems. This study focuses on patients with a shockable rhythm and aims to improve their outcomes.

Out-of-Hospital Cardiac Arrest>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCardiologyInternal Medicine

ARDS Treatment: Recombinant Human Plasma Gelsolin

We are studying whether intravenous recombinant human plasma gelsolin is safe and may help patients with moderate-to-severe ARDS caused by pneumonia or infections. This trial compares it to a placebo alongside standard care.

Acute Respiratory Distress Syndrome (ARDS)≤3 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementInfectious DiseasesPulmonology

Metastatic Squamous Non-Small Cell Lung Cancer: Pembrolizumab Study

We are studying the effects of pembrolizumab alone or with MK-2870 in patients with metastatic squamous non-small cell lung cancer. The goal is to see which treatment may improve survival and quality of life.

Squamous Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Cerebral Amyloid Angiopathy: ALN-APP Treatment Study

We are studying a new treatment called ALN-APP for patients with Cerebral Amyloid Angiopathy. The goal is to see if it helps reduce new brain bleeding and improve overall brain health.

Cerebral Amyloid Angiopathy1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteNeurology

Sufentanil for Pain Management in Abdominal Surgery

We are studying how the use of sufentanil during non-major abdominal surgery affects long-term pain and recovery. This trial looks at both immediate and chronic pain experiences in patients.

Chronic Postsurgical Pain>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesGastroenterologyInternal MedicineOtolaryngology

Systemic Lupus Erythematosus: Rapcabtagene Autoleucel Study

We are studying a new treatment for people with difficult-to-treat kidney disease caused by systemic lupus erythematosus. The goal is to see if it works better than standard care in improving kidney health.

Systemic Lupus Erythematosus with Lupus Nephritis1-2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteInternal MedicineNephrologyRheumatology

Myelodysplastic Syndromes: Ivosidenib vs. Azacitidine

We are studying the effects of a new drug, ivosidenib, in adults with myelodysplastic syndromes who have an IDH1 mutation. The goal is to understand its effectiveness and safety compared to azacitidine.

Myelodysplastic Syndrome (MDS)Hypomethylating Agent Naive Myelodysplastic Syndromes>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Thyroid Eye Disease: Sirolimus vs. Corticosteroids

We are comparing a new treatment called Sirolimus with corticosteroids for people with active thyroid eye disease. The goal is to see if Sirolimus is more effective and has fewer side effects.

Thyroid Eye Disease≤3 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteEndocrinologyOphthalmology

Long-Term Study of Galapagos CAR T-Cell Therapies

We are evaluating the long-term safety and effectiveness of Galapagos CAR T-cell therapies in patients. This study aims to understand how these treatments work over many years.

Relapsed/Refractory B-Cell Non-Hodgkin LymphomaRelapsed/Refractory Multiple MyelomaRelapsed/Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)>2 yearsConfirmation phase (III)16-20 visitsNo PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Rheumatoid Arthritis: Proactive Drug Monitoring Study

We are investigating whether proactive monitoring of a TNF inhibitor helps adults with rheumatoid arthritis maintain better disease control without flare-ups compared to standard care.

Rheumatoid Arthritis1-2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboInvestigational MedicinesRheumatology

High-Grade Soft Tissue Sarcoma: Ifosfamide and Doxorubicin Study

We are studying a combination of chemotherapy drugs for patients with localized high-grade soft tissue sarcoma. The goal is to see how well this treatment works and to understand its safety and impact on quality of life.

Soft Tissue SarcomaEfficacy phase (II)No PlaceboStandard MedicinesOncology

Recurrent Glioblastoma: Personalized Drug Strategy

We are testing a personalized treatment approach for patients with recurrent glioblastoma to see if tailored drug combinations improve tumor response and overall survival. The study also looks at any side effects from the treatments.

Recurrent Glioblastoma1-2 yearsSafety phase (I)No PlaceboStandard MedicinesNeurologyOncology

GSDIa: DTX401 Treatment Study

We are examining the long-term safety and pregnancy outcomes of DTX401 for individuals with GSDIa. This study will help us understand how effective this treatment is over time.

Glycogen Storage Disease Type IA>2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboInvestigational MedicinesPartially RemoteEndocrinologyInternal Medicine

Multiple Sclerosis: Stem Cell Treatment Study

We are investigating whether a new stem cell treatment can help regenerate nerve function in patients with progressive multiple sclerosis. The study will also assess safety and other health measures.

Multiple Sclerosis>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesNeurology

BCR/ABL1-Like Acute Lymphoblastic Leukemia: Ponatinib and Chemotherapy

We are studying a new treatment combining ponatinib and chemotherapy for adults with BCR/ABL1-like acute lymphoblastic leukemia. The aim is to improve remission rates and monitor disease response over time.

Acute Lymphoblastic LeukemiaEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Rare Cancers: Dendritic Cell Vaccine Study

We are testing a new vaccine made from patients' own tumor cells for those with resected stage IV neuroendocrine tumors and soft tissue sarcomas. The study aims to evaluate safety and how well the immune system responds to the treatment.

Soft Tissue SarcomaNeuroendocrine Tumors>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology